 Megan Kelsey
Concepts (274)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetes Mellitus, Type 2 | 34 | 2023 | 2094 | 4.400 |
Why?
| | Insulin Resistance | 16 | 2023 | 1072 | 3.570 |
Why?
| | Puberty | 10 | 2022 | 135 | 3.440 |
Why?
| | Pediatric Obesity | 12 | 2021 | 488 | 3.290 |
Why?
| | Hypoglycemic Agents | 8 | 2022 | 1008 | 1.930 |
Why?
| | Bariatric Surgery | 7 | 2022 | 161 | 1.490 |
Why?
| | Obesity, Morbid | 8 | 2022 | 197 | 1.460 |
Why?
| | Obesity | 16 | 2023 | 2507 | 1.440 |
Why?
| | Metformin | 6 | 2021 | 276 | 1.410 |
Why?
| | Adolescent | 54 | 2023 | 17830 | 1.390 |
Why?
| | Prediabetic State | 6 | 2021 | 219 | 1.270 |
Why?
| | Body Mass Index | 14 | 2022 | 1956 | 1.190 |
Why?
| | Insulin-Secreting Cells | 3 | 2021 | 317 | 1.070 |
Why?
| | Testosterone | 6 | 2022 | 343 | 0.980 |
Why?
| | Adolescent Behavior | 3 | 2020 | 489 | 0.960 |
Why?
| | Health Behavior | 3 | 2020 | 704 | 0.910 |
Why?
| | Child | 38 | 2022 | 18402 | 0.860 |
Why?
| | Blood Glucose | 12 | 2021 | 1819 | 0.830 |
Why?
| | Hypothalamic Neoplasms | 1 | 2022 | 9 | 0.800 |
Why?
| | Body Composition | 4 | 2021 | 590 | 0.800 |
Why?
| | Hypothalamic Diseases | 1 | 2022 | 17 | 0.790 |
Why?
| | Cardiovascular Diseases | 7 | 2023 | 1727 | 0.740 |
Why?
| | Insulin | 6 | 2021 | 2076 | 0.640 |
Why?
| | Female | 48 | 2023 | 59461 | 0.630 |
Why?
| | Menstruation Disturbances | 1 | 2018 | 12 | 0.620 |
Why?
| | Polycystic Ovary Syndrome | 4 | 2021 | 141 | 0.620 |
Why?
| | Adipose Tissue | 3 | 2021 | 539 | 0.610 |
Why?
| | Gonadal Steroid Hormones | 1 | 2019 | 124 | 0.610 |
Why?
| | Humans | 64 | 2023 | 114616 | 0.590 |
Why?
| | Transgender Persons | 1 | 2020 | 134 | 0.570 |
Why?
| | Male | 39 | 2023 | 55549 | 0.560 |
Why?
| | Clinical Trials as Topic | 1 | 2021 | 931 | 0.550 |
Why?
| | Body Weight | 1 | 2020 | 868 | 0.540 |
Why?
| | Glucose Tolerance Test | 6 | 2021 | 343 | 0.520 |
Why?
| | Diabetes Mellitus, Type 1 | 3 | 2022 | 3244 | 0.500 |
Why?
| | Sex Factors | 4 | 2019 | 1715 | 0.480 |
Why?
| | Cross-Sectional Studies | 10 | 2021 | 4405 | 0.460 |
Why?
| | Brain Neoplasms | 1 | 2022 | 979 | 0.460 |
Why?
| | Leptin | 1 | 2015 | 210 | 0.440 |
Why?
| | Muscle Fatigue | 1 | 2014 | 94 | 0.430 |
Why?
| | Mass Screening | 3 | 2022 | 1004 | 0.430 |
Why?
| | Task Performance and Analysis | 1 | 2014 | 159 | 0.430 |
Why?
| | Disease Progression | 1 | 2020 | 2380 | 0.420 |
Why?
| | Thinness | 1 | 2013 | 87 | 0.420 |
Why?
| | Biomarkers | 4 | 2020 | 3405 | 0.390 |
Why?
| | Depression | 2 | 2023 | 1133 | 0.380 |
Why?
| | Off-Label Use | 2 | 2022 | 51 | 0.380 |
Why?
| | Cohort Studies | 8 | 2021 | 4894 | 0.360 |
Why?
| | Life Style | 4 | 2021 | 430 | 0.350 |
Why?
| | Metabolic Syndrome | 4 | 2020 | 321 | 0.350 |
Why?
| | Androgens | 2 | 2022 | 167 | 0.320 |
Why?
| | Muscle, Skeletal | 3 | 2014 | 1472 | 0.320 |
Why?
| | Sex Hormone-Binding Globulin | 2 | 2019 | 48 | 0.320 |
Why?
| | Reference Values | 2 | 2020 | 742 | 0.310 |
Why?
| | Weight Gain | 2 | 2022 | 453 | 0.300 |
Why?
| | Estradiol | 3 | 2022 | 455 | 0.300 |
Why?
| | Bone Density | 2 | 2023 | 432 | 0.300 |
Why?
| | Ribonuclease III | 2 | 2021 | 34 | 0.300 |
Why?
| | DEAD-box RNA Helicases | 2 | 2021 | 56 | 0.290 |
Why?
| | Case-Control Studies | 6 | 2021 | 3001 | 0.290 |
Why?
| | Pituitary Neoplasms | 2 | 2021 | 157 | 0.270 |
Why?
| | Fructosamine | 2 | 2016 | 14 | 0.260 |
Why?
| | Deoxyglucose | 2 | 2016 | 43 | 0.260 |
Why?
| | Diabetes, Gestational | 2 | 2023 | 281 | 0.260 |
Why?
| | Germ-Line Mutation | 3 | 2021 | 130 | 0.250 |
Why?
| | Young Adult | 10 | 2023 | 10455 | 0.250 |
Why?
| | Risk Factors | 7 | 2023 | 8628 | 0.250 |
Why?
| | Serum Albumin | 2 | 2016 | 137 | 0.250 |
Why?
| | Follow-Up Studies | 7 | 2023 | 4411 | 0.240 |
Why?
| | Age Factors | 3 | 2021 | 2894 | 0.230 |
Why?
| | Gastrointestinal Microbiome | 2 | 2021 | 500 | 0.230 |
Why?
| | Aging | 1 | 2014 | 1618 | 0.230 |
Why?
| | Radius | 2 | 2023 | 33 | 0.220 |
Why?
| | Hypoglycemia | 2 | 2019 | 386 | 0.220 |
Why?
| | Glucose Clamp Technique | 2 | 2015 | 181 | 0.220 |
Why?
| | Longitudinal Studies | 3 | 2023 | 2387 | 0.210 |
Why?
| | Sleep | 2 | 2018 | 631 | 0.210 |
Why?
| | Colorado | 4 | 2020 | 4099 | 0.210 |
Why?
| | Population Health | 1 | 2023 | 42 | 0.200 |
Why?
| | Hypertension | 2 | 2021 | 1056 | 0.200 |
Why?
| | Bariatrics | 1 | 2021 | 5 | 0.190 |
Why?
| | Obesity Management | 1 | 2021 | 8 | 0.190 |
Why?
| | Blast Crisis | 1 | 2021 | 20 | 0.190 |
Why?
| | Overnutrition | 1 | 2021 | 30 | 0.180 |
Why?
| | Anti-Obesity Agents | 1 | 2021 | 45 | 0.180 |
Why?
| | Treatment Outcome | 6 | 2021 | 9084 | 0.180 |
Why?
| | Prognosis | 4 | 2021 | 3328 | 0.180 |
Why?
| | Randomized Controlled Trials as Topic | 3 | 2023 | 1214 | 0.180 |
Why?
| | Hyperinsulinism | 1 | 2021 | 103 | 0.180 |
Why?
| | Hypogonadism | 1 | 2010 | 75 | 0.180 |
Why?
| | Iatrogenic Disease | 1 | 2020 | 49 | 0.180 |
Why?
| | Bone and Bones | 1 | 2023 | 278 | 0.170 |
Why?
| | Diabetic Ketoacidosis | 1 | 2022 | 159 | 0.170 |
Why?
| | Gastric Bypass | 1 | 2021 | 92 | 0.170 |
Why?
| | Exercise | 3 | 2023 | 1644 | 0.170 |
Why?
| | Hospitals, Pediatric | 2 | 2022 | 480 | 0.170 |
Why?
| | Prospective Studies | 5 | 2021 | 6214 | 0.170 |
Why?
| | ACTH-Secreting Pituitary Adenoma | 1 | 2009 | 6 | 0.170 |
Why?
| | Linear Models | 2 | 2019 | 768 | 0.170 |
Why?
| | Cushing Syndrome | 1 | 2009 | 10 | 0.170 |
Why?
| | Klinefelter Syndrome | 1 | 2020 | 50 | 0.170 |
Why?
| | Class I Phosphatidylinositol 3-Kinases | 1 | 2019 | 76 | 0.170 |
Why?
| | Sexual Maturation | 1 | 2019 | 47 | 0.170 |
Why?
| | Capillaries | 1 | 2019 | 91 | 0.170 |
Why?
| | Growth Hormone | 1 | 2019 | 103 | 0.170 |
Why?
| | Pseudohypoaldosteronism | 1 | 2009 | 2 | 0.160 |
Why?
| | Time Factors | 3 | 2021 | 6112 | 0.160 |
Why?
| | Dyslipidemias | 1 | 2021 | 154 | 0.160 |
Why?
| | Research | 1 | 2022 | 394 | 0.160 |
Why?
| | Drug Administration Schedule | 1 | 2021 | 718 | 0.160 |
Why?
| | Gastrectomy | 1 | 2020 | 82 | 0.160 |
Why?
| | Vascular Malformations | 1 | 2019 | 47 | 0.160 |
Why?
| | Oligonucleotides, Antisense | 1 | 2009 | 100 | 0.160 |
Why?
| | Reproductive Health | 1 | 2019 | 71 | 0.160 |
Why?
| | Double-Blind Method | 2 | 2021 | 1660 | 0.160 |
Why?
| | Drug Therapy, Combination | 2 | 2019 | 951 | 0.160 |
Why?
| | Hyperkalemia | 1 | 2009 | 26 | 0.160 |
Why?
| | Analysis of Variance | 2 | 2019 | 1226 | 0.160 |
Why?
| | Fatty Liver | 1 | 2021 | 210 | 0.160 |
Why?
| | Weight Reduction Programs | 1 | 2019 | 94 | 0.160 |
Why?
| | Psychotherapy, Group | 1 | 2018 | 61 | 0.150 |
Why?
| | Exome | 1 | 2019 | 200 | 0.150 |
Why?
| | Diet | 2 | 2017 | 1080 | 0.150 |
Why?
| | Risk Reduction Behavior | 1 | 2020 | 201 | 0.150 |
Why?
| | Aspartate Aminotransferases | 1 | 2018 | 86 | 0.150 |
Why?
| | Overweight | 1 | 2022 | 471 | 0.150 |
Why?
| | Adenoma | 1 | 2009 | 189 | 0.140 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2009 | 329 | 0.140 |
Why?
| | Depressive Disorder | 1 | 2020 | 332 | 0.140 |
Why?
| | Adult | 10 | 2022 | 30528 | 0.140 |
Why?
| | United States | 8 | 2022 | 12176 | 0.140 |
Why?
| | Academic Medical Centers | 1 | 2019 | 410 | 0.140 |
Why?
| | Biodiversity | 1 | 2020 | 349 | 0.140 |
Why?
| | Retrospective Studies | 6 | 2022 | 12542 | 0.140 |
Why?
| | Hydrocortisone | 1 | 2018 | 267 | 0.140 |
Why?
| | Adiposity | 1 | 2021 | 457 | 0.140 |
Why?
| | Diabetic Nephropathies | 1 | 2019 | 234 | 0.140 |
Why?
| | Human Development | 1 | 2016 | 14 | 0.140 |
Why?
| | Hyperglycemia | 2 | 2016 | 291 | 0.130 |
Why?
| | Triglycerides | 2 | 2020 | 467 | 0.130 |
Why?
| | Prenatal Exposure Delayed Effects | 1 | 2021 | 452 | 0.130 |
Why?
| | Pilot Projects | 1 | 2020 | 1372 | 0.120 |
Why?
| | Adiponectin | 1 | 2016 | 213 | 0.120 |
Why?
| | Sex Characteristics | 1 | 2019 | 640 | 0.120 |
Why?
| | Algorithms | 1 | 2022 | 1466 | 0.120 |
Why?
| | Risk | 1 | 2017 | 812 | 0.120 |
Why?
| | Neoplasms, Complex and Mixed | 1 | 2014 | 7 | 0.120 |
Why?
| | Bacteria | 1 | 2020 | 725 | 0.110 |
Why?
| | Fasting | 1 | 2014 | 240 | 0.110 |
Why?
| | Lipolysis | 1 | 2013 | 39 | 0.110 |
Why?
| | Observer Variation | 1 | 2014 | 295 | 0.110 |
Why?
| | Feeding Behavior | 1 | 2018 | 574 | 0.110 |
Why?
| | Nervous System Physiological Phenomena | 1 | 2013 | 21 | 0.110 |
Why?
| | Pediatrics | 1 | 2020 | 979 | 0.100 |
Why?
| | Adolescent Health Services | 1 | 2013 | 68 | 0.100 |
Why?
| | Nutrition Policy | 1 | 2013 | 54 | 0.100 |
Why?
| | Nutrition Assessment | 1 | 2013 | 75 | 0.100 |
Why?
| | Fatty Acids, Nonesterified | 1 | 2013 | 151 | 0.100 |
Why?
| | Electromyography | 1 | 2014 | 326 | 0.100 |
Why?
| | Gene-Environment Interaction | 1 | 2014 | 183 | 0.100 |
Why?
| | Diabetes Mellitus | 1 | 2020 | 900 | 0.100 |
Why?
| | Weight Loss | 3 | 2021 | 641 | 0.100 |
Why?
| | Polyendocrinopathies, Autoimmune | 1 | 2011 | 18 | 0.100 |
Why?
| | Physical Fitness | 1 | 2013 | 179 | 0.100 |
Why?
| | Mutation | 3 | 2019 | 3344 | 0.100 |
Why?
| | Biomechanical Phenomena | 1 | 2014 | 668 | 0.090 |
Why?
| | Muscle Contraction | 1 | 2014 | 389 | 0.090 |
Why?
| | Potassium Channels | 1 | 2011 | 121 | 0.090 |
Why?
| | Genome-Wide Association Study | 3 | 2023 | 1177 | 0.090 |
Why?
| | Absorptiometry, Photon | 2 | 2023 | 224 | 0.090 |
Why?
| | Non-alcoholic Fatty Liver Disease | 1 | 2014 | 245 | 0.090 |
Why?
| | Blood Glucose Self-Monitoring | 1 | 2014 | 498 | 0.090 |
Why?
| | Postoperative Complications | 1 | 2021 | 2127 | 0.090 |
Why?
| | Patient Education as Topic | 1 | 2015 | 680 | 0.090 |
Why?
| | Tibia | 2 | 2023 | 166 | 0.090 |
Why?
| | Pregnancy | 4 | 2023 | 5517 | 0.080 |
Why?
| | Motor Activity | 1 | 2013 | 640 | 0.080 |
Why?
| | Child, Preschool | 4 | 2022 | 9106 | 0.070 |
Why?
| | Infant | 4 | 2021 | 7954 | 0.060 |
Why?
| | Glycation End Products, Advanced | 2 | 2016 | 57 | 0.060 |
Why?
| | Polymorphism, Single Nucleotide | 2 | 2023 | 1879 | 0.060 |
Why?
| | Genetic Predisposition to Disease | 3 | 2021 | 2084 | 0.060 |
Why?
| | Stomach Neoplasms | 1 | 2004 | 65 | 0.060 |
Why?
| | Cadherins | 1 | 2004 | 175 | 0.050 |
Why?
| | Comorbidity | 2 | 2021 | 1448 | 0.050 |
Why?
| | Animals | 3 | 2019 | 31692 | 0.050 |
Why?
| | Genetic Testing | 1 | 2004 | 379 | 0.050 |
Why?
| | KCNQ1 Potassium Channel | 1 | 2021 | 4 | 0.050 |
Why?
| | Receptor, Melanocortin, Type 4 | 1 | 2021 | 11 | 0.050 |
Why?
| | Bacteroidetes | 1 | 2021 | 20 | 0.050 |
Why?
| | Nutrition Disorders | 1 | 2021 | 22 | 0.050 |
Why?
| | Transferrin | 1 | 2021 | 39 | 0.050 |
Why?
| | Firmicutes | 1 | 2021 | 17 | 0.050 |
Why?
| | Intra-Abdominal Fat | 1 | 2021 | 77 | 0.050 |
Why?
| | Remission Induction | 1 | 2021 | 233 | 0.040 |
Why?
| | Neoplasms | 1 | 2014 | 2097 | 0.040 |
Why?
| | Polymicrogyria | 1 | 2019 | 6 | 0.040 |
Why?
| | Waist Circumference | 1 | 2020 | 122 | 0.040 |
Why?
| | Precision Medicine | 1 | 2023 | 336 | 0.040 |
Why?
| | Heart | 1 | 2023 | 612 | 0.040 |
Why?
| | Mice, Obese | 1 | 2009 | 53 | 0.040 |
Why?
| | Fludrocortisone | 1 | 2009 | 3 | 0.040 |
Why?
| | Mineralocorticoids | 1 | 2009 | 3 | 0.040 |
Why?
| | Epithelial Sodium Channels | 1 | 2009 | 12 | 0.040 |
Why?
| | Renin | 1 | 2009 | 31 | 0.040 |
Why?
| | Citrates | 1 | 2009 | 43 | 0.040 |
Why?
| | Aldosterone | 1 | 2009 | 42 | 0.040 |
Why?
| | Dissection | 1 | 2009 | 51 | 0.040 |
Why?
| | Pedigree | 2 | 2014 | 460 | 0.040 |
Why?
| | Craniotomy | 1 | 2009 | 68 | 0.040 |
Why?
| | DNA Mutational Analysis | 2 | 2014 | 372 | 0.040 |
Why?
| | Vitamin D Deficiency | 1 | 2021 | 158 | 0.040 |
Why?
| | Infant, Newborn | 2 | 2019 | 5040 | 0.040 |
Why?
| | Pituitary Gland | 1 | 2009 | 148 | 0.040 |
Why?
| | Potassium | 1 | 2009 | 128 | 0.040 |
Why?
| | RNA, Ribosomal, 16S | 1 | 2021 | 485 | 0.040 |
Why?
| | Feces | 1 | 2021 | 373 | 0.040 |
Why?
| | Sodium Chloride | 1 | 2009 | 136 | 0.040 |
Why?
| | Genotype | 1 | 2023 | 1760 | 0.040 |
Why?
| | Psychiatric Status Rating Scales | 1 | 2020 | 482 | 0.040 |
Why?
| | Gene Frequency | 1 | 2019 | 477 | 0.040 |
Why?
| | Homeodomain Proteins | 1 | 2021 | 463 | 0.040 |
Why?
| | Qualitative Research | 1 | 2022 | 934 | 0.040 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2009 | 923 | 0.040 |
Why?
| | Magnetic Resonance Imaging | 2 | 2021 | 3039 | 0.030 |
Why?
| | Survival Rate | 1 | 2021 | 1644 | 0.030 |
Why?
| | Hospitals | 1 | 2021 | 581 | 0.030 |
Why?
| | Referral and Consultation | 1 | 2021 | 632 | 0.030 |
Why?
| | Blotting, Western | 1 | 2009 | 1147 | 0.030 |
Why?
| | Glomerular Filtration Rate | 1 | 2019 | 604 | 0.030 |
Why?
| | Area Under Curve | 1 | 2016 | 274 | 0.030 |
Why?
| | Electrocardiography | 1 | 2009 | 560 | 0.030 |
Why?
| | Monitoring, Ambulatory | 1 | 2016 | 81 | 0.030 |
Why?
| | Decision Support Techniques | 1 | 2019 | 355 | 0.030 |
Why?
| | Surveys and Questionnaires | 2 | 2020 | 4620 | 0.030 |
Why?
| | Dietary Supplements | 1 | 2009 | 460 | 0.030 |
Why?
| | C-Peptide | 1 | 2015 | 138 | 0.030 |
Why?
| | Incidence | 1 | 2021 | 2311 | 0.030 |
Why?
| | Prevalence | 1 | 2021 | 2249 | 0.030 |
Why?
| | Family Health | 1 | 2015 | 193 | 0.030 |
Why?
| | Pandemics | 1 | 2022 | 1317 | 0.030 |
Why?
| | Fatal Outcome | 1 | 2014 | 284 | 0.030 |
Why?
| | RNA | 1 | 2009 | 809 | 0.030 |
Why?
| | Radiography, Thoracic | 1 | 2014 | 150 | 0.030 |
Why?
| | Mice | 2 | 2019 | 14859 | 0.030 |
Why?
| | Mice, Knockout | 1 | 2019 | 2565 | 0.030 |
Why?
| | Anthropometry | 1 | 2013 | 182 | 0.030 |
Why?
| | Fruit | 1 | 2013 | 127 | 0.020 |
Why?
| | Vegetables | 1 | 2013 | 133 | 0.020 |
Why?
| | Nutrition Surveys | 1 | 2013 | 224 | 0.020 |
Why?
| | Self Concept | 1 | 2013 | 213 | 0.020 |
Why?
| | Liver | 1 | 2009 | 1633 | 0.020 |
Why?
| | Middle Aged | 3 | 2021 | 26719 | 0.020 |
Why?
| | Antibodies, Monoclonal, Murine-Derived | 1 | 2011 | 82 | 0.020 |
Why?
| | Dietary Fats | 1 | 2013 | 287 | 0.020 |
Why?
| | Rituximab | 1 | 2011 | 150 | 0.020 |
Why?
| | Syndrome | 1 | 2011 | 333 | 0.020 |
Why?
| | Energy Intake | 1 | 2013 | 427 | 0.020 |
Why?
| | Quality of Life | 1 | 2021 | 2353 | 0.020 |
Why?
| | Mice, Inbred C57BL | 1 | 2009 | 4689 | 0.020 |
Why?
| | Immunohistochemistry | 1 | 2014 | 1629 | 0.020 |
Why?
| | Psychometrics | 1 | 2013 | 608 | 0.020 |
Why?
| | Immunologic Factors | 1 | 2011 | 220 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2016 | 2762 | 0.020 |
Why?
| | Predictive Value of Tests | 1 | 2013 | 1796 | 0.020 |
Why?
| | Brain | 1 | 2019 | 2371 | 0.020 |
Why?
| | Parents | 1 | 2015 | 1186 | 0.020 |
Why?
| | Severity of Illness Index | 1 | 2013 | 2537 | 0.020 |
Why?
| | Lung Diseases | 1 | 2011 | 701 | 0.020 |
Why?
| | Tomography, X-Ray Computed | 1 | 2014 | 2279 | 0.020 |
Why?
| | Autoantibodies | 1 | 2011 | 1345 | 0.010 |
Why?
| | Mutation, Missense | 1 | 2004 | 293 | 0.010 |
Why?
| | Genetic Variation | 1 | 2004 | 870 | 0.010 |
Why?
| | Aged | 1 | 2004 | 19061 | 0.000 |
Why?
|
|
Kelsey's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|